سوق الهيبارين في الشرق الأوسط وأفريقيا - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HEPARIN MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE MIDDLE EAST AND AFRICA HEPARIN MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 MIDDLE EAST AND AFRICA HEPARIN MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.1.1 PATENT LANDSCAPE

6.1.2 USPTO NUMBER

6.1.3 PATENT EXPIRY

6.1.4 EPIO NUMBER

6.1.5 PATENT STRENGTH AND QUALITY

6.1.6 PATENT CLAIMS

6.1.7 PATENT CITATIONS

6.1.8 PATENT LITIGATION AND LICENSING

6.1.9 FILE OF PATENT

6.1.10 PATENT RECEIVED CONTRIES

6.1.11 TECHNOLOGY BACKGROUND

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH SPECIALIST

6.8 OTHER KOL SNAPSHOTS

7 EPIDEMIOLOGY

7.1 INCIDENCE OF ALL BY GENDER

7.2 TREATMENT RATE

7.3 MORTALITY RATE

7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

7.5 PATIENT TREATMENT SUCCESS RATES

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 REGULATORY FRAMEWORK

9.1 REGULATORY APPROVAL PROCESS

9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

9.3 REGULATORY APPROVAL PATHWAYS

9.4 LICENSING AND REGISTRATION

9.5 POST-MARKETING SURVEILLANCE

9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

10 PIPELINE ANALYSIS

10.1 CLINICAL TRIALS AND PHASE ANALYSIS

10.2 DRUG THERAPY PIPELINE

10.3 PHASE III CANDIDATES

10.4 PHASE II CANDIDATES

10.5 PHASE I CANDIDATES

10.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

11 MARKETED DRUG ANALYSIS

11.1 DRUG

11.1.1 BRAND NAME

11.1.2 GENERICS NAME

11.2 THERAPEUTIC INDICTION

11.3 PHARMACOLOGICAL CLASS OF THE DRUG

11.4 DRUG PRIMARY INDICATION

11.5 MARKET STATUS

11.6 MEDICATION TYPE

11.7 DRUG DOSAGES FORM

11.8 DOSAGES AVAILABILITY

11.9 DRUG ROUTE OF ADMINISTRATION

11.1 DOSING FREQUENCY

11.11 DRUG INSIGHT

11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

11.12.1 FORECAST MARKET OUTLOOK

11.12.2 CROSS COMPETITION

11.12.3 THERAPEUTIC PORTFOLIO

11.12.4 CURRENT DEVELOPMENT SCENARIO

12 MARKET ACCESS

12.1 10-YEAR MARKET FORECAST

12.2 CLINICAL TRIAL RECENT UPDATES

12.3 ANNUAL NEW FDA APPROVED DRUGS

12.4 DRUGS MANUFACTURER AND DEALS

12.5 MAJOR DRUG UPTAKE

12.6 CURRENT TREATMENT PRACTICES

12.7 IMPACT OF UPCOMING THERAPY

13 R & D ANALYSIS

13.1 COMPARATIVE ANALYSIS

13.2 DRUG DEVELOPMENTAL LANDSCAPE

13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

13.4 THERAPEUTIC ASSESSMENT

13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

14 MARKET OVERVIEW

14.1 DRIVERS

14.2 RESTRAINTS

14.3 OPPORTUNITIES

14.4 CHALLENGES

15 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY AVAILABILITY

15.1 OVERVIEW

15.2 RAW

15.3 PROCESSED

16 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY SOURCE

16.1 OVERVIEW

16.2 BIOLOGICAL

16.2.1 BOVINE

16.2.2 PROCINE

16.3 SYNTHETIC

17 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY PRODUCT TYPE

17.1 OVERVIEW

17.2 UNFRACTIONATED HEPARIN (UFH)

17.2.1 MARKET VALUE (USD MILLION)

17.2.2 MARKET VOLUME

17.2.3 AVERAGE SELLING PRICE (USD)

17.3 LOW MOLECULAR WEIGHT HEPARIN (LMWH)

17.3.1 ENOXAPARIN

17.3.1.1. MARKET VALUE (USD MILLION)

17.3.1.2. MARKET VOLUME

17.3.1.3. AVERAGE SELLING PRICE (USD)

17.3.2 DALTEPARIN

17.3.2.1. MARKET VALUE (USD MILLION)

17.3.2.2. MARKET VOLUME

17.3.2.3. AVERAGE SELLING PRICE (USD)

17.3.3 TINZAPARIN

17.3.3.1. MARKET VALUE (USD MILLION)

17.3.3.2. MARKET VOLUME

17.3.3.3. AVERAGE SELLING PRICE (USD)

17.3.4 FRAXIPARINE

17.3.4.1. MARKET VALUE (USD MILLION)

17.3.4.2. MARKET VOLUME

17.3.4.3. AVERAGE SELLING PRICE (USD)

17.3.5 NADROPARIN

17.3.5.1. MARKET VALUE (USD MILLION)

17.3.5.2. MARKET VOLUME

17.3.5.3. AVERAGE SELLING PRICE (USD)

17.3.6 OTHERS

17.4 ULTRA-LOW MOLECULAR WEIGHT HEPARIN (ULMWH)

17.4.1 SEMULOPARIN

17.4.1.1. MARKET VALUE (USD MILLION)

17.4.1.2. MARKET VOLUME

17.4.1.3. AVERAGE SELLING PRICE (USD)

17.4.2 BEMIPARIN

17.4.2.1. MARKET VALUE (USD MILLION)

17.4.2.2. MARKET VOLUME

17.4.2.3. AVERAGE SELLING PRICE (USD)

17.4.3 OTHERS

18 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY SALT TYPE

18.1 OVERVIEW

18.2 SODIUM

18.3 CALCIUM

18.4 OTHERS

19 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY TYPE

19.1 OVERVIEW

19.2 BRANDED

19.2.1 FRAGMIN

19.2.2 LOVENOX

19.2.3 INNOHEP

19.2.4 LIPO-HEPIN

19.2.5 LIQUAEMIN

19.2.6 PANHEPARIN

19.2.7 HEP-LOCK

19.2.8 HEPALEAN (CALCIPARINE)

19.2.9 OTHERS

19.3 GENERICS

20 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY THERAPEUTICS

20.1 OVERVIEW

20.2 CARDIOVASCULAR

20.2.1 DEEP VEIN THROMBOSIS

20.2.2 PULMONARY EMBOLISM

20.2.3 ARTERIAL THROMBOEMBOLISM

20.2.4 MYOCARDIAL INFARCTION

20.2.5 ATRIAL FIBRILLATION

20.2.6 PERIPHERAL ARTERY DISEASE

20.3 RESPIRATORY

20.3.1 DEEP VEIN THROMBOSIS

20.3.2 PULMONARY EMBOLISM

20.3.3 ARTERIAL THROMBOEMBOLISM

20.3.4 ATRIAL FIBRILLATION

20.3.5 PERIPHERAL ARTERY DISEASE

20.4 ONCOLOGY

20.4.1 DEEP VEIN THROMBOSIS

20.4.2 PULMONARY EMBOLISM

20.4.3 ARTERIAL THROMBOEMBOLISM

20.4.4 ATRIAL FIBRILLATION

20.4.5 PERIPHERAL ARTERY DISEASE

20.5 NEPHROLOGY

20.5.1 DEEP VEIN THROMBOSIS

20.5.2 PULMONARY EMBOLISM

20.5.3 ARTERIAL THROMBOEMBOLISM

20.5.4 ATRIAL FIBRILLATION

20.5.5 PERIPHERAL ARTERY DISEASE

20.6 CNS

20.6.1 DEEP VEIN THROMBOSIS

20.6.2 PULMONARY EMBOLISM

20.6.3 ARTERIAL THROMBOEMBOLISM

20.6.4 ATRIAL FIBRILLATION

20.6.5 PERIPHERAL ARTERY DISEASE

20.7 OTHERS

21 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY MODE OF ADMINISTRATION

21.1 OVERVIEW

21.2 ORAL

21.3 PARENTAL

21.3.1 SUBCUTANEOUS

21.3.2 INTRAVENOUS

21.3.3 INTRAPERITONEAL

21.4 OTHERS

22 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY STRENGTH

22.1 OVERVIEW

22.2 10 UNIT

22.3 100 UNIT

22.4 1000 UNIT

22.5 5000 UNIT

22.6 10,000 UNIT

22.7 25,000 UNIT

22.8 OTHERS

23 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY CONTAINER TYPE

23.1 OVERVIEW

23.2 BOTTLES

23.3 BAGS

23.4 VIALS

23.5 OTHERS

24 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY PACKAGING MATERIAL

24.1 OVERVIEW

24.2 GLASS

24.3 PLASTIC

25 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY APPLICATION

25.1 OVERVIEW

25.2 PRE-SURGICAL PROCEDURES

25.3 POST-SURGICAL PROCEDURES

25.4 KIDNEY DIALYSIS

25.5 DIAGNOSTIC TESTS

25.6 OTHERS

26 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 PRIVATE

26.2.1.1. TIER 1

26.2.1.2. TIER 2

26.2.1.3. TIER 3

26.2.2 PUBLIC

26.2.2.1. TIER 1

26.2.2.2. TIER 2

26.2.2.3. TIER 3

26.3 SPECIALTY CLINICS

26.4 AMBULATORY SURGICAL CENTERS

26.5 HOME HEALTHCARE

26.6 OTHERS

27 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDER

27.3 RETAIL SALES

27.3.1 HOSPITAL PHARMACY

27.3.2 RETAIL PHARMACY

27.3.3 ONLINE PHARMACY

27.4 OTHERS

28 MIDDLE EAST AND AFRICA HEPARIN MARKET, SWOT AND DBMR ANALYSIS

29 MIDDLE EAST AND AFRICA HEPARIN MARKET, COMPANY LANDSCAPE

29.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

29.2 MERGERS & ACQUISITIONS

29.3 NEW PRODUCT DEVELOPMENT & APPROVALS

29.4 EXPANSIONS

29.5 REGULATORY CHANGES

29.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

30 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY REGION

MIDDLE EAST AND AFRICA HEPARIN MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

30.1 MIDDLE EAST AND AFRICA

30.1.1 SOUTH AFRICA

30.1.2 EGYPT

30.1.3 BAHRAIN

30.1.4 KUWAIT

30.1.5 OMAN

30.1.6 QATAR

30.1.7 SAUDI ARABIA

30.1.8 UNITED ARAB EMIRATES

30.1.9 REST OF MEA

30.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

31 MIDDLE EAST AND AFRICA HEPARIN MARKET, COMPANY PROFILE

31.1 SANOFI

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPMENTS

31.2 PFIZER INC.

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPMENTS

31.3 FRESENIUS KABI

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPMENTS

31.4 F. HOFFMANN-LA ROCHE LTD

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPMENTS

31.5 VIATRIS INC.

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPMENTS

31.6 ASPEN GLOBAL INCORPORATED.

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPMENTS

31.7 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPMENTS

31.8 EISAI CO., LTD.

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPMENTS

31.9 HIKMA PHARMACEUTICALS PLC

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPMENTS

31.1 LEO PHARMA

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPMENTS

31.11 SHANGHAI FOSUN PHARMACEUTICAL（GROUP）CO., LTD.

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPMENTS

31.12 PHARMACIA AND UPJOHN COMPANY LLC (DISTRIBUTED BY - PFIZER)

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPMENTS

31.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPMENTS

31.14 SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPMENTS

32 RELATED REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH